Theravance's Vibativ gains partial support from FDA panel

12/3/2012 | American City Business Journals

An FDA advisory panel endorsed the approval of Theravance's once-daily antibiotic Vibativ to treat patients with hospital-acquired pneumonia when other alternatives are not suitable. But the drug failed to win the advisory committee's approval recommendation as a first-line therapy for the condition, also known as nosocomial pneumonia. Trial data failed to offer "substantial evidence" of Vibativ's safety and efficacy against hospital-acquired pneumonia, the panel said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX